Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 20/20 | 0.70 |
| ▸ | MMP13 | P45452 | 17/20 | 0.66 |
| ▸ | MMP1 | P03956 | 16/20 | 0.55 |
| ▸ | MMP9 | P14780 | 15/20 | 0.55 |
| ▸ | MMP2 | P08253 | 3/20 | 0.53 |
| ▸ | MMP14 | P50281 | 2/20 | 0.53 |
| ▸ | MMP7 | P09237 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088548 | 0.88 | ADAM17 (0.57) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL4088543 | 0.88 | ADAM17 (0.56) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL4088729 | 0.88 | ADAM17 (0.59) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL4087256 | 0.80 | ADAM17 (0.57) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL4078599 | 0.79 | ADAM17 (0.58) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL4082261 | 0.77 | ADAM17 (0.51) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6815599 | 0.71 | ADAM17 (1.00) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL3941469 | 0.70 | ADAM17 (0.77) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL3942145 | 0.70 | ADAM17 (0.81) | ADAM17MMP13MMP1MMP9 | |
| SCHEMBL3949565 | 0.69 | MMP13 (0.78) | ADAM17MMP13MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485667-B2 | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2009-02-03 | — | — | US | claimed |
| US-7199155-B2 | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-04-03 | — | — | US | claimed |
| WO-2005021489-A2 | ACETYLENIC ARYL SULFONATE HYDROXAMIC ACID TACE AND MATRIX METALLOPROTEINASE INHIBITORS | WYETH HOLDINGS CORPORATION (US) | 2005-03-10 | — | — | WO | claimed |
| US-20040127524-A1 | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-7485667-B2 | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485667-B2 | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485667-B2 | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-20070155834-A1 | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155834-A1 | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155834-A1 | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-7199155-B2 | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199155-B2 | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199155-B2 | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| WO-2005021489-A2 | ACETYLENIC ARYL SULFONATE HYDROXAMIC ACID TACE AND MATRIX METALLOPROTEINASE INHIBITORS | WYETH HOLDINGS CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20040127524-A1 | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040127524-A1 | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040127524-A1 | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155834-A1 | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | TNF, SI, TNFRSF1A | ADAM17 25/4885MMP13 83/4885MMP1 15/4885 |
| US-20040127524-A1 | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors | SI, MMP1, MMP12 | ADAM17 18/4885MMP13 76/4885MMP1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.